Breakthrough science is changing our understanding of cognitive longevity.

Bevimi Uno sources its omega-3 fatty acids (DHA and EPA) from Norwegian herring caviar rather than standard fish oil because the omega-3s in herring caviar are delivered in phospholipid form. This distinction matters especially for people who carry the APOE4 gene variant — the strongest known genetic risk factor for Alzheimer's disease. APOE4 carriers have impairedtransportof standard triglyceride-form omega-3s across the blood-brain barrier. Phospholipid-form omega-3s bypass this transport limitation, ensuring that even the highest-risk individuals can deliver DHA and EPA to their brain cells effectively. Additionally, herring caviar naturallycontainsspecialized pro-resolving mediators (SPMs), which are signaling molecules that actively resolve inflammation and trigger cellular debris removal — a process called efferocytosis — in aging or diseased brain tissue.

Specialized pro-resolving mediators, or SPMs, are a class of bioactive lipid molecules that the body produces to actively resolve inflammation and initiate tissue repair. Unlike anti-inflammatory drugs that simply suppress inflammation, SPMs trigger the final phase of the inflammatory response: they signal immune cells to stop releasing inflammatory molecules, begin clearing cellular debris through a process called efferocytosis, and promote tissue healing. In the context of brain health, SPMs play a critical role in resolving neuroinflammation — the chronic brain inflammation that drives cognitive decline. However, as people age or develop neurodegenerative conditions, the brain's ability to produce SPMs often diminishes.BevimiUno delivers standardized SPMs directly,essentially providingthe brain's natural resolution machinery to help break the cycle of chronic neuroinflammation.

Quercetin, mangiferin, and ginseng ginsenosides each act on distinct but complementary anti-neuroinflammatory pathways within the gut–nerve–brain axis. Quercetin is a polyphenol with well-documented neuroprotective and anti-inflammatory mechanisms, including modulation of NF-kB signaling and reduction of pro-inflammatory cytokine release from activated microglia. Mangiferin, a polyphenolic compound, has demonstrated the ability to mitigate neurodegeneration and neuroinflammation in published research, working through antioxidant and immune-modulatory pathways. Bevimi Uno sources rare ginsenosides (including Rg3 and Rh2) through a Belgian biotech partnership that produces an extract mimicking the chemical profile of a 20-year-old wild ginseng root — compounds with high central nervous system activity and established neuroprotective effects against ischemic and inflammatory brain injury. Together, these three ingredients provide active neuroinflammation reduction while the LL-37-boosting nutrients address the upstream infectious triggers.

Vitamin D3 is one of the five essential nutrients in Bevimi Uno that stimulates the CAMP gene, which encodes the LL-37 antimicrobial peptide. Published research has demonstrated that vitamin D3, working through the vitamin D receptor, is a primary driver of cathelicidin (LL-37) expression in human epithelial and immune cells. However, vitamin D3 requires adequate magnesium to be metabolized effectively — which is why Bevimi Uno includes both nutrients together. Beyond LL-37 induction, vitamin D3 supports immune regulation, helps maintain the integrity of the blood-brain barrier, and has been associated with reduced risk of cognitive decline in observational studies. Bevimi Uno's formulation ensures that vitamin D3 works synergistically with magnesium, DHA, curcumin, and EGCG to maximize LL-37 production.

Choline is an essential nutrient that the body cannot produce in sufficient quantities on its own, making dietary intake critical. In the brain, choline serves as the precursor to acetylcholine — one of the most important neurotransmitters for memory, learning, and attention. Choline is also a key structural component of phosphatidylcholine, the primary phospholipid in neuronal cell membranes, making it essential for maintaining membrane integrity and synaptic function. Published research has established choline's neuroprotective effects, including support for methyl donation pathways that regulate gene expression in brain tissue. In Bevimi Uno's formulation, choline works alongside DHA to reinforce neuronal membrane health and synaptic resilience — providing direct brain and nerve support while the formula's other ingredients address the upstream infectious and inflammatory drivers of neurodegeneration.

We strictly avoid synthetic, high-intensity artificial sweeteners—and the latest science validates this choice. Emerging research on cognitive dysfunction has raised serious red flags regarding popular artificial sugar substitutes. A major 8-year prospective study recently published in the medical journal Neurology linked the high consumption of certain low-calorie synthetic sweeteners and sugar alcohols to an accelerated rate of cognitive decline, specifically impacting memory and verbal fluency. Many artificial sweeteners are also known to disrupt the gut microbiome, which directly impairs the gut-brain axis and can trigger neuroinflammation. By utilizing Allulose alongside other naturally derived options, we deliver a naturally sweet profile that protects your long-term cognitive health rather than putting it at risk.

Neuroinflammation is now recognized by leading researchers as a central driver of cognitive decline across most neurological disorders, including Alzheimer's disease, Parkinson's disease, and post-COVID brain fog. A 2025 review in the journal Science confirmed neuroinflammation as a unifying feature of these conditions. The process works like this: chronic infections or environmental stressors activate immune cells in the brain (microglia and astrocytes), which release inflammatory molecules. While short-term activation is protective, persistent inflammation creates a destructive cycle — damaging neurons, disrupting the blood-brain barrier, and impairing the brain's ability to clear toxic protein aggregates like amyloid-beta and tau. This is why targeting neuroinflammation early, before symptoms appear, is considered one of the most important modifiable strategies for preserving long-term cognitive health.

Systemic inflammation is a whole-body immune response measured by markers like C-reactive protein (CRP), while neuroinflammation refers specifically to inflammatory processes occurring within the brain and central nervous system. Neuroinflammation is primarily driven by two specialized brain immune cells: microglia and astrocytes. When these cells detect threats — such as infections, amyloid protein deposits, or traumatic injury — they release pro-inflammatory cytokines including TNF-alpha, IL-1-beta, and IL-6. The critical challenge with neuroinflammation is that it can become self-sustaining: inflammatory signaling damages neurons, which generates more cellular debris, which triggers more immune activation, creating a feed-forward cycle of injury. Bevimi Uno addresses both systemic and neuroinflammation through complementary mechanisms — LL-37 controls systemic immune activation and microbial triggers, while quercetin, mangiferin, SPMs, and ginseng specifically target inflammatory signaling along the gut–nerve–brain axis.

Chronic stress is a significant and often underestimated driver of neuroinflammation and cognitive decline. Prolonged activation of the body's stress response system — the hypothalamic-pituitary-adrenal (HPA) axis — maintains elevated levels of glucocorticoids (stress hormones) that have direct neurotoxic effects on the hippocampus, the brain's memory center. Sustained glucocorticoid exposure inhibits the growth of new neurons (neurogenesis), especially in the dentate gyrus; causes existing neurons to lose synaptic connections through dendritic atrophy; activates microglia and astrocytes to release pro-inflammatory cytokines that contribute to neuronal death; and reduces levels of brain-derived neurotrophic factor (BDNF) — a protein essential for neuronal survival and learning. Chronic stress can tilt the entire neurological system toward a pro-inflammatory state, compounding any ongoing neuroinflammatory processes driven by infections or other environmental triggers. Bevimi Uno's anti-neuroinflammatory ingredients — quercetin, mangiferin, SPMs, and ginseng — are specifically included to help counteract the inflammatory cascade that chronic stress accelerates.

Even mild traumatic brain injury (TBI) can act as a biological amplifier within the gut–brain–immune network. Mechanical trauma to the brain initiates microglial activation, blood-brain barrier disruption, and mitochondrial dysfunction — changes that mirror those seen in chronic infection or viral reactivation. Within hours of injury, TBI induces a systemic inflammatory response characterized by elevated circulating cytokines (IL-1-beta, TNF-alpha, IL-6) that disrupt tight junction proteins in the intestinal lining, producing intestinal hyperpermeability and bacterial translocation into circulation. This acute inflammatory burst can persist for years, creating a "primed" neuroimmune environment highly susceptible to secondary triggers such as infection, metabolic stress, or chronic cortisol exposure. Trauma to the head has also been shown to reactivate latent HSV-1 and varicella zoster virus infections, which are increasingly recognized as key drivers of dementia development. Patients with repeated mild TBI often show elevated neurofilament light (NfL) and phosphorylated tau (pTau-217) levels years after injury — biomarkers that overlap with early Alzheimer's disease.

Post-COVID brain fog — affecting an estimated 28 percent of COVID-19 patients according to a 2024 study of 25,800 individuals — is increasingly understood as a manifestation of persistent neuroinflammation triggered by the SARS-CoV-2 virus. COVID-19 infection can activate microglia, disrupt the blood-brain barrier, trigger systemic inflammatory cascades, and potentially reactivate latent herpes viruses in the nervous system — mechanisms that closely parallel the infectious neuroinflammatory pathways implicated in Alzheimer's and Parkinson's disease. Patients with long-COVID brain fog often present with elevated inflammatory markers, reduced omega-3 status, and impaired cognitive processing that persists months after the initial infection. Bevimi Uno's multi-pathway formulation targets these same mechanisms: LL-37 upregulation strengthens antiviral and antimicrobial defense, SPMs and anti-inflammatory polyphenols calm the neuroinflammatory response, and DHA and choline support neuronal membrane repair and synaptic recovery.

LL-37 is a naturally occurring antimicrobial peptide produced by the human body as part of the innate immune system. It is the only human cathelicidin peptide, and it plays a critical role in brain health through four distinct mechanisms: it kills harmful bacteria, fungi, and viruses that are linked to neurodegeneration; it binds to amyloid-beta protein to inhibit the plaque formation associated with Alzheimer's disease; it controls inflammation by preventing excessive immune activation and shifting the body toward healing; and it activates autophagy — the cellular cleanup process that clears damaged proteins and pathogens from the brain. LL-37 is found throughout the body, with especially high concentrations in the gut and brain. However, LL-37 activity naturally declines with age, which is one reason why Bevimi Uno was specifically formulated to restore and enhance LL-37 levels using five synergistic natural nutrients.

The amyloid hypothesis has been the dominant explanation for Alzheimer's disease for decades, proposing that accumulation of amyloid-beta (Aβ) protein in the brain is the primary event triggering neurodegeneration and cognitive decline. However, recent advances in molecular understanding have cast significant doubt on this framework as a complete causal explanation. While FDA-approved drugs like aducanumab and lecanemab can clear amyloid from the brain, they demonstrate only marginal clinical benefits while carrying significant adverse side effects — suggesting that amyloid may be more symptom than root cause. Current research increasingly points toward chronic infection, neuroinflammation, immune dysfunction, and gut–brain axis disruption as upstream drivers that precede and promote amyloid accumulation. Bevimi Uno's formulation reflects this evolving scientific understanding by targeting these upstream mechanisms rather than focusing on amyloid alone.

LL-37 has been shown in published research to bind directly to the amyloid-beta (Aβ) peptide — the protein fragment that aggregates into the plaques found in Alzheimer's disease brains. By binding to Aβ, LL-37 disrupts the process of fibril assembly, preventing individual peptide molecules from clustering into the insoluble plaques that drive neuroinflammation and neuronal damage. LL-37 also binds to alpha-synuclein, the amyloidogenic protein implicated in Parkinson's disease, further preventing pathological amyloid formation. This dual anti-amyloid activity is significant because it suggests that maintaining healthy LL-37 levels may provide protection against both Alzheimer's and Parkinson's disease through a single biological mechanism. Bevimi Uno's formulation uses five nutrients — vitamin D3, magnesium, DHA, curcumin, and EGCG — that are each known to stimulate the CAMP gene responsible for LL-37 production.

LL-37 production depends on adequate levels of vitamin D3, magnesium, and other cofactors that commonly become deficient as people age. As LL-37 activity declines, the body's ability to perform several critical protective functions diminishes simultaneously: antimicrobial defense weakens, allowing chronic infections like P. gingivalis and latent herpes viruses to persist or reactivate; the natural inhibition of amyloid plaque formation is reduced; the inflammatory balancing function is impaired, leading to unchecked chronic inflammation; and autophagy — the cellular cleanup of damaged proteins and pathogens — slows down. This convergence of declining defenses helps explain why neurodegenerative disease risk increases dramatically with age. Bevimi Uno was designed to counteract this age-related decline by providing the specific nutrients required for LL-37 expression in the CAMP gene pathway, effectively restoring a key component of the body's innate neuroprotective system.

Autophagy is the body's natural cellular cleanup process — a mechanism by which cells break down and recycle damaged proteins, dysfunctional mitochondria, and intracellular pathogens. In the brain, healthy autophagy is essential for clearing the protein aggregates (like amyloid-beta and tau) that accumulate in Alzheimer's and Parkinson's disease. When autophagy becomes impaired — through aging, chronic infection, or inflammation — these toxic materials build up and drive progressive neurodegeneration. LL-37, the antimicrobial peptide that Bevimi Uno is formulated to boost, has been shown to activate autophagy by stimulating the AMPK pathway and inhibiting mTOR signaling. This means that by enhancing LL-37 levels, Bevimi Uno supports the brain's ability to continuously clear harmful debris, helping break the cycle of protein accumulation and chronic neuroinflammation that underlies cognitive decline.

LL-37 activates autophagy — the brain's cellular self-cleaning process — through two well-characterized molecular signaling pathways. First, LL-37 stimulates AMP-activated protein kinase (AMPK), an energy-sensing enzyme that signals cells to initiate recycling of damaged components when resources are limited. Second, LL-37 inhibits the mechanistic target of rapamycin (mTOR), a nutrient-sensing pathway that normally suppresses autophagy when active. By simultaneously activating AMPK and inhibiting mTOR, LL-37 creates a strong pro-autophagic signal within brain cells. This is critical because impaired autophagy is a hallmark of neurodegenerative disease — when the brain cannot efficiently clear amyloid-beta aggregates, phosphorylated tau tangles, damaged mitochondria, and intracellular pathogens, these toxic materials accumulate and fuel a cycle of progressive neuroinflammation and neuronal death. Restoring LL-37 levels through Bevimi Uno's CAMP gene-activating ingredients supports this essential cellular maintenance process.

Mitochondrial dysfunction is increasingly recognized as a key contributor to Alzheimer's disease pathology and broader cognitive decline. Mitochondria — the energy-producing organelles in every cell — are especially critical in the brain, which consumes roughly 20 percent of the body's energy despite representing only 2 percent of body mass. When mitochondria are damaged by chronic infection, viral intoxication, oxidative stress, or traumatic injury, neurons lose their energy supply and become vulnerable to degeneration. Damaged mitochondria also release reactive oxygen species that amplify neuroinflammation and trigger further cellular damage. In the neurodegenerative cascade described by Bevimi's scientific team, bacterial and viral co-infection of the brain leads to progressive mitochondrial damage, which suppresses immunity and autophagy in brain tissue, eventually resulting in cognitive decline. LL-37's autophagy-activating properties support mitophagy — the selective clearance of damaged mitochondria — helping restore healthy cellular energy metabolism.

Bevimi Uno contains five specific nutrients — vitamin D3, magnesium, DHA, curcumin, and EGCG — that are each independently documented in peer-reviewed research to upregulate the human CAMP gene, which encodes the LL-37 antimicrobial peptide. These five nutrients are considered obligate (required) for increasing CAMP gene transcription, meaning that deficiency in any one of them can limit LL-37 production. Vitamin D3 activates CAMP gene expression through the vitamin D receptor, but requires adequate magnesium for proper metabolism. DHA supports cell membrane fluidity necessary for immune signaling. Curcumin induces CAMP gene expression through a vitamin D receptor-independent pathway, providing an additional route to LL-37 production. EGCG from green tea demonstrates synergistic antimicrobial activity alongside LL-37. By delivering all five nutrients together in a highly bioavailable liquid format, Bevimi Uno ensures that none of the essential cofactors for LL-37 production are missing.

The gut–brain–immune axis is the bidirectional communication network that connects your digestive system, nervous system, and immune system. Your gut contains trillions of microorganisms that directly influence brain function through nerve pathways (including the vagus nerve), immune signaling molecules, and metabolic products. When this system is disrupted — through chronic infection, inflammation, poor diet, or stress — harmful bacteria and viruses can suppress immune defenses, travel through nerve pathways to the brain, and trigger the neuroinflammation that drives cognitive decline. Bevimi Uno is formulated to support all three components of this axis simultaneously: strengthening antimicrobial immunity in the gut, calming inflammatory signals along nerve pathways, and reinforcing the brain's natural repair and defense mechanisms.

Neurotropic pathogens — including herpes simplex virus 1 (HSV-1) and human cytomegalovirus (hCMV) — can reach the brain by traveling through nerve pathways that bypass the blood-brain barrier entirely. The vagus nerve, which runs from the gut to the brainstem, and the trigeminal nerves, which connect the oral cavity to the brain, serve as direct conduits for viral transport because there is no blood-brain barrier within these nerve fibers. In addition to live viral particles, the oral pathobiont P. gingivalis releases outer membrane vesicles that can transport its enzymatic virulence factors (gingipains) along these same nerve pathways. P. gingivalis-infected host cells also release extracellular vesicles carrying gingipain virulence factors. Once these pathogens and toxins reach the brain, they cause progressive mitochondrial damage, suppress local immunity, and impair autophagy — triggering the chronic neuroinflammatory cascade associated with cognitive decline.

Candida albicans (C. albicans) is a common fungal organism that has been shown to form dual biofilms with P. gingivalis in the oral cavity and gut. Research demonstrates that when C. albicans is present alongside P. gingivalis, it enhances the bacterium's ability to adhere to tissues, survive in aerobic environments, and express its virulent properties — making P. gingivalis more dangerous. This synergistic relationship between fungal and bacterial pathogens may help explain the well-documented epidemiological link between hyperglycemia, metabolic dysfunction, and increased dementia risk, since elevated blood sugar promotes Candida overgrowth. Bevimi Uno's formulation addresses this fungal–bacterial synergy through LL-37, which has demonstrated potent antifungal activity against C. albicans in addition to its antibacterial and antiviral properties, providing broad-spectrum antimicrobial defense across the gut–brain axis.

The blood-brain barrier (BBB) is a highly selective membrane formed by tightly connected endothelial cells that line the brain's blood vessels. It acts as a gatekeeper, allowing essential nutrients and oxygen to pass while blocking pathogens, toxins, and inflammatory molecules from entering brain tissue. When the BBB breaks down — due to chronic inflammation, traumatic injury, infection, or aging — it becomes permeable to harmful substances that accelerate neurodegeneration. BBB breakdown is now recognized as an early event in Alzheimer's disease, occurring before significant amyloid or tau accumulation. Inflammatory cytokines, bacterial toxins like P. gingivalis lipopolysaccharide (LPS), and sustained glucocorticoid exposure from chronic stress can all compromise BBB integrity by degrading tight junction proteins. Bevimi Uno's formulation addresses BBB protection through multiple pathways: LL-37 binds microbial products like LPS to prevent excessive inflammatory signaling, SPMs promote endothelial repair, and anti-neuroinflammatory compounds reduce the cytokine burden that damages barrier integrity.